News Releases
- August 23, 2019
- Cantargia and BioWa extend ongoing collaboration around the POTELLIGENT® Technology
- August 8, 2018
- Kyowa Kirin Announces FDA Approval of Poteligeo® (mogamulizumab-kpkc), a POTELLIGENT® antibody for the Treatment of Mycosis Fungoides and Sézary Syndrome
- March 22, 2018
- Lonza and BioWa Sign POTELLIGENT® CHOK1SVTM Cell Line Technology Licensing Agreement with Tillotts Pharma AG PDF
- March 22, 2018
- Kyowa Hakko Kirin and BioWa Obtain Successful Settlement of United States Patent Infringement Lawsuit against Aragen Bioscience and Transposagen
- October 18, 2016
- Kyowa Hakko Kirin and BioWa File Suit in the U.S. to Defend Patent Rights on POTELLIGENT® Technology
- April 1, 2016
- BioWa Announces Office Relocation to Princeton, NJ and appointment of New President and CEO
- January 11, 2016
- BioWa opens POTELLIGENT® Technology license to customers for creating POTELLIGENT® cell lines
- June 26, 2015
- Cantargia licenses BioWa POTELLIGENT® Technology platform for production of lead product candidate
- February 16, 2015
- Transfer of BioWa's "External Innovation Engine" In-Licensing Activities to Kyowa Hakko Kirin California
- March 19, 2014
- Lonza and BioWa Sign POTELLIGENT® CHOK1SV Cell Line Technology Licensing Agreement with arGEN-X
- December 11, 2013
- Lonza and BioWa Sign POTELLIGENT® CHOK1SV Cell Line Technology
Licensing Agreement with MedImmune
- July 30, 2013
- BioWa and Lonza Sign License Agreements with Pfizer
- March 18, 2013
- BioWa Relocates to La Jolla, CA
Technologies
Evolution of enhanced antibody activity technologies – POTELLIGENT® and COMPLEGENT®
